Investor Presentation

AI summary - Q1 FY27 consolidated revenue ₹873 Cr, +13% YoY; EBITDA ₹296 Cr, +7% YoY; PAT ₹143 Cr, +14.5% YoY - Domestic Branded Formulations revenue ₹801 Cr, +14.2% YoY; EBITDA margin 35% - Broad-based growth with 7 of 10 therapies posting double-digit growth; OAD and Cardiac segments yet to regain full momentum - Insulin segment market share up from 9% to 16% post Biocon acquisition; pipeline of 5 insulin analog products launching from FY28 - GLP-1 (Semaglutide) market leader with ~20% unit share; early leadership in next big IPM market - Swiss Parenterals business stable; EU CAPA actions underway, audit readiness targeted by Dec-26 - Capex of ₹88 Cr in Q1 FY27; operating cash flow at 77% of EBITDA - Key priorities: grow OAD and Cardiac segments, commercialize Eris Bionxt, enter insulin analogs market, complete Swiss Parenterals CAPA